Disney patents metaverse theme park technology during the last week of December as we can see more today in our latest cryptocurrency news. Disney has been...
Reports of a new COVID variant emerged over the weekend from Cyprus that they dubbed “deltacron” as it had a genetic makeup similar to both delta...
The Nasdaq Composite is now down about 8.0% since the start of the year on fears of inflation and rate hikes, but Ally Invest’s Lindsey Bell...
Consumer stocks could be on investors’ radar amid a red-hot economy. The post Best Consumer Stocks To Buy In 2022? 5 To Check Out appeared first...
The pandemic has undeniably expedited innovation. As people were forced to isolate themselves, major industries had to pivot to accommodate. That is no more true than...
Will these penny stocks see a short squeeze this week? The post Short Squeeze Penny Stocks To Buy Now? 4 To Watch Under $5 appeared first...
Understanding the difference between COVID tests can help explain why the rules keep changing.
The COVID-19 pandemic has brought to light the incredible power of collaboration in the life science industry. About 40 percent of Pfizer’s portfolio was realized through partnerships, and...
High levels of T-cells from common cold coronaviruses can provide protection against COVID-19, an Imperial College London study published on January 10 found, which could inform...
- by New Deal democratSo, how “mild” or not, is Omicron? It depends on whether you lag the data on hospitalizations and deaths or not.The original...
Key Events In The "Massive Week Ahead" After a relatively quiet start to the year on the economic event front, if not in markets where last...
Turley: Supreme Court Considers Trip To 'Major-Questions-Land' Over Vaccine Mandates Authored by Jonathan Turley, Below is my column in the Hill on the vaccine mandate cases...
French startup Doctolib held a (virtual) press conference this morning to share some metrics, look back at the company’s recent product launches and give a hint...
Canada’s strategy must include global engagement. Without it, we will be living on borrowed time, waiting for a new variant, a new booster, a new quick...
Nearly two months after getting the boot from the NIH’s ACTIV-3 study over a failed futility analysis, Novartis and Molecular Partners are back with mid-stage results...